白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

张路; 李剑

doi:10.12290/xhyxzz.2023-0227

白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

doi: 10.12290/xhyxzz.2023-0227

张路,
李剑^,

中国医学科学院北京协和医院血液内科, 北京 100730

基金项目:

中央高水平医院医院临床科研专项（2022-PUMCH-A-021）；北京市科技计划课题（Z211100002921016）；北京市东城区优秀人才培养经费（2022-dchrcpyzz-69)

详细信息

通讯作者:
李剑,E-mail:lijian@pumch.cn

中图分类号: R552；R825.5；R730.51
计量
- 文章访问数: 42
- HTML全文浏览量: 3
- PDF下载量: 15
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-08
- 录用日期: 2023-06-26
- 网络出版日期: 2023-07-17

Castleman Disease in China: State-of-the-art Before the Era of IL-6 Targeted Therapy

ZHANG Lu,
LI Jian^,

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National High Level Hospital Clinical Research Funding (2022-PUMCH-A-021)； Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Sciences and Technology(Z211100002921016)； Dongcheng District Outstanding Talent Nurturing Program (2022-dchrcpyzz-69)

摘要

摘要: Castleman病（ Castleman disease，CD）是纳入我国《第一批罕见病目录》的罕见血液系统疾病，该病临床异质性强，分为多种亚型。其中，特发性多中心型Castleman病（idiopathic Multicentric Castleman Disease，iMCD）病情重、预后差，是临床医师面临的重大挑战。白细胞介素（interleukin，IL）-6靶向药物（如司妥昔单抗）是国内外多个指南、共识推荐治疗iMCD的首选药物，2022年7月司妥昔单抗在国内上市，标志着我国针对iMCD的IL-6靶向治疗时代开启。值此特殊时间节点，本文阐述过去20年间（IL-6靶向治疗前时代）中国Castleman病的诊疗现状，以及国内研究者在该领域取得的研究成果。
- Castleman病 /
- 罕见病 /
- 临床研究
Abstract: Castleman disease (CD) is a group of rare and heterogenous hematological diseases which is included in the ‘ Rare disease catalogue’ of China. Among the different clinical subtypes of CD， idiopathic Multicentric Castleman Disease (iMCD) is characterized by symptomatic inflammatory symptoms with poor prognosis. Interleukin-6 (IL-6) targeted therapy (eg. siltuximab) is now considered as the most important treatment option according to international and domestic treatment guidelines and consensus. Since July， 2022， siltuximab became available in Chinese market which heralds the era of IL-6 targeted therapy in China. Thus， it is a good time point to review the state-of-the-art in the field of diagnosis and treatment of CD. We also would highlight some of the clinical investigations conducted by Chinese researchers in this commentary.
- Castleman disease /
- rare disease /
- clinical research

HTML全文

参考文献(13)

[1]	Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J].Cancer 1956, 9:822-830.
[2]	Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac. 2023, 34:100720.
[3]	van Rhee F, Voorhees P, Dispenzieri A, et al.International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J].Blood,2018, 132:2115-2124.
[4]	Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J].Blood,2017, 129:1646-1657.
[5]	中华医学会血液学分会淋巴细胞疾病学组,中国抗癌协会血液肿瘤专业委员会,中国Castleman病协作组.中国Castleman病诊断与治疗专家共识(2021年版)[J].中华血液学杂志, 2021, 42:529-534.
[6]	Zhang MY, Jia MN, Chen J, et al.UCD with MCD-like inflammatory state:surgical excision is highly effective[J].Blood Adv, 2021,5:122-128.
[7]	Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease[J]. Ann Hematol,2018,97:1641- 1647.
[8]	Zhang L, Zhao AL, Duan MH, et al.Phase 2 study using oral thalidomidecyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood,2019,133:1720-1728.
[9]	Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease[J]. Leukemia, 2019, 33:1035-1038.
[10]	Yu L, Shi M, Cai Q, et al. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease:The International Castleman Disease Consortium Study[J].Oncologist, 2020,25:963-973.
[11]	Zhou J, Zhang L, Liu X, et al. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified:From Nodules to Cysts or Consolidation[J].Chest,2023.doi: 10.1016/j.chest.2023.03.022.
[12]	Zhao H, Zhang M, Shen K, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients[J]. Blood, 2023, 141:2654-2657.
[13]	Zhong NN, Liu B, Bu LL. Exploring Castleman disease in China:pre-IL-6 treatment era and advancements in knowledge[J]. Lancet Reg Health West Pac, 2023, 34:100747.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 42
HTML全文浏览量: 3
PDF下载量: 15
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

doi: 10.12290/xhyxzz.2023-0227

通讯作者: 李剑,E-mail:lijian@pumch.cn

计量

出版历程

Castleman Disease in China: State-of-the-art Before the Era of IL-6 Targeted Therapy

计量

出版历程

目录

通讯作者:
李剑,E-mail:lijian@pumch.cn